
Illustration: Annelise Capossela/Axios
Big drugmakers are shifting more licensing-deal value to future milestones, with upfront cash representing a smaller share, per a JPMorgan-DealForma report reviewed exclusively by Axios Pro.
Why it matters: Biotechs must meet specified milestones before collecting much of a licensing deal's potential value, delaying access to capital.
By the numbers: Disclosed upfront cash represented just 6% of total announced deal value through Q3, down from 7% in each of the previous three years and 13% in 2019.
- Through Q3, 35 disclosed licensing deals included upfront cash payments of at least $100 million, compared with 46 in all of 2025.
The big picture: Announced licensing value reached $221.1 billion through Q3, up from $181.5 billion during the same period in 2025, as drugmakers look outside their pipelines for new products.
Case in point: AstraZeneca agreed to pay CSPC $1.2 billion upfront in a weight-management deal worth up to $18.5 billion, including milestones.
What they're saying: "Licensing has stepped up as a pretty viable option for financing for companies," says George Santo, a managing director at JPMorgan. "That is their lifeblood."
Yes, but: Full-year licensing value is unlikely to surpass 2025's $274.3 billion but is expected to exceed annual totals from 2017 through 2024, per the report.
Zoom in: Biologics, small-molecule and genomics are among the top modalities attracting licensing upfront cash and equity this year.
Stunning stat: China-originated drug assets are taking up a larger share of licensing deals, representing more than half of global Big Pharma licensing deals with upfront payments north of $50 million, per the report.
- That's up from 39% in 2025 and 18% in 2023.
- "More competition for these assets is driving up upfronts," Santo says.
What we're watching: Macroeconomic uncertainty and rising interest rates could slow the pace of licensing deals and reduce their size.
- The SPDR S&P Biotech ETF (XBI) reached a five-year high in August but was down about 6% over the month through Oct. 15.
- "It bears watching," Santo says. But "I wouldn't call it the end of performance at this point."
